News

This interview at Fall Clinical highlights a session on clinical pearls related to diagnosing prurigo nodularis in patients with skin of color.

Pooled results from two Phase 3 trials show DFD-29 achieved a 62.7% IGA success rate and significantly greater lesion reduction than both doxycycline and placebo.

Although no direct correlation can be drawn, these findings suggest a possible ocular benefit from GLP-1 RAs compared to other weight loss drugs.

These recent findings on roflumilast cream (Zoryve) highlight the topical agent’s efficacy and impacts on quality of life in younger patients with atopic dermatitis.

At Week 52, icotrokinra achieved clear/almost clear skin in 72% of patients with scalp psoriasis and 85% with genital psoriasis, with consistent safety and durable responses.

Advanced CKD shows higher rates of certain ERCP complications but not post-ERCP pancreatitis compared with the general population.

A real-world study found that using baked goods with sesame paste was safer than raw sesame seeds for oral immunotherapy.

Findings from a prespecified analysis of the phase 3 MAESTRO-NASH trial highlight resmetirom’s consistent benefit with background SGLT2i or GLP-1 RA treatment.

Risks of myocardial infarction, stroke, heart failure, and other debilitating cardiovascular diseases may be directly influenced by adolescent sugar intake.

Lilly's lebrikizumab-lbkz treatment, used once every 8 weeks, resulted in durable disease control in moderate-to-severe atopic dermatitis.

Perceived behavioral control emerged as a predictor of immunosuppression adherence after kidney transplantation, pointing to practical intervention targets.

This interview highlights the takeaways from Nestor’s Fall Clinical session titled ‘What Did 2025 Bring to the Table in Dermatology?’

Roger discusses how new therapies are transforming asthma treatment, enabling potential clinical remission.

Landers discusses the importance of including multiple specialized professionals and sharing the decision-making process in cardiovascular care.

Among patients with primary hyperoxaluria and CKD, those with delayed CKD diagnosis were more likely to encounter greater healthcare burdens.

A study finds older adults with depression and comorbid anxiety show less improvement after accelerated theta burst stimulation.

Findings suggest having GERD incurs an 18% greater risk of a new AUD diagnosis, presenting an opportunity to discuss alcohol use with patients.

Saxena discusses lorundrostat’s efficacy in lowering systolic blood pressure regardless of additional antihypertensive medications.

This systematic review and meta-analysis highlights tildrakizumab’s efficacy in Asian patients versus the efficacy of other biologic options.

Right transcutaneous auricular VNS (taVNS) acutely increases food liking in patients with MDD, especially those with high anhedonia, a study found.

GLP-1 RAs may offer benefits beyond adiposity reduction in patients with atherosclerotic cardiovascular disease.

FDA launches the Commissioner’s National Priority Voucher program, expediting drug reviews for critical health needs.

Assaf shares insights into how to navigate patient profiles and treatment options to optimize severe asthma care with biologics.

Data from the phase 4 head-to-head EVEREST trial further indicates dupilumab's benefit for type 2 inflammatory airway disease.

This conference preview for the 2025 Fall Clinical Dermatology meeting highlights upcoming sessions and interviews.

A large analysis reveals clinically relevant differences in weight, blood pressure, and heart rate across 30 antidepressants.

Mucus plugs are an increasingly present issue in uncontrolled asthma. Lugogo discusses promising findings from VESTIGE that addresses them.